Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Reumatología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Terminado
Fase 2
ClinicalTrials.gov
A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase 2 Study to Evaluate the Safety and Efficacy of LY3337641 in Adult Subjects With Rheumatoid Arthritis: The RAjuvenate Study
INTERVENTIONAL
Inicio: 22 de ago de 2016
ID: NCT02628028
Completado
Fase 3
ClinicalTrials.gov
A Multicenter, Randomized, Double-blind, Placebo-controlledTrial of Golimumab, a Fully Human Anti-TNFa MonoclonalAntibody, Administered Subcutaneously, in Subjects With ActiveRheumatoid Arthritis Despite Methotrexate Therapy
INTERVENTIONAL
Inicio: 1 de dic de 2005
ID: NCT00264550
Activo, no recluta
Fase 2
ClinicalTrials.gov
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Dose Levels of ESK-001 in Adult Patients With Systemic Lupus Erythematosus
INTERVENTIONAL
Inicio: 26 de jun de 2023
ID: NCT05966480
Completado
Fase 3
ClinicalTrials.gov
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™)a Fully Human Monoclonal Anti-BLyS Antibody in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 or HGS1006-C1057
INTERVENTIONAL
Inicio: 30 de may de 2008
ID: NCT00712933
Terminado
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
INTERVENTIONAL
Inicio: 22 de ene de 2013
ID: NCT01714817
Completado
Fase 2
ClinicalTrials.gov
Assessment Of Safety, Efficacy, PK&PD Of BG9924 in RA Patients Who Have Had An Inadequate Response To Conventional DMARD Therapy.
INTERVENTIONAL
Inicio: 1 de jul de 2007
ID: NCT00664716
Completado
Fase 2
ClinicalTrials.gov
A Multicenter, Randomized, Double-blind, PlacebO-controlled, Parallel-group Study to EValuate the Efficacy and Safety of JTE-051 Administered for 12 Weeks to Subjects With Active Rheumatoid Arthritis (MOVE-RA)
INTERVENTIONAL
Inicio: 14 de sept de 2016
ID: NCT02919475
Completado
Fase 2
ClinicalTrials.gov
A Phase 2a, Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Study of JNJ-40346527 in Subjects With Active Rheumatoid Arthritis Despite Disease-modifying Antirheumatic Drug Therapy
INTERVENTIONAL
Inicio: 1 de jul de 2012
ID: NCT01597739
Terminado
Fase 2
ClinicalTrials.gov
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of BIIB023 in Subjects With Lupus Nephritis
INTERVENTIONAL
Inicio: 1 de jul de 2012
ID: NCT01499355
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-naïve Participants With Active Psoriatic Arthritis
INTERVENTIONAL
Inicio: 21 de feb de 2025
ID: NCT06878404
Completado
Fase 2
ClinicalTrials.gov
A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus
INTERVENTIONAL
Inicio: 19 de ene de 2017
ID: NCT02908100
Completado
Fase 1
ClinicalTrials.gov
A Phase Ib, Open-Label, Multicenter Study to Investigate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab Following Subcutaneous Administration to Patients With Systemic Juvenile Idiopathic Arthritis
INTERVENTIONAL
Inicio: 15 de ago de 2013
ID: NCT01904292
Activo, no recluta
Fase 2
ClinicalTrials.gov
A Multi-Center, Open-Label Trial to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Subcutaneously Administered Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Participants With Systemic Lupus Erythematosus (SLE)
INTERVENTIONAL
Inicio: 28 de nov de 2019
ID: NCT04179032
Completado
Fase 2
ClinicalTrials.gov
A Two-Cohort Randomized Phase II, Double-Blind, Parallel Group Study in Patients With Active Rheumatoid Arthritis Evaluating the Efficacy and Safety of GDC-0853 Compared With Placebo and Adalimumab in Patients With an Inadequate Response to Previous Methotrexate Therapy (Cohort 1) and Compared With Placebo in Patients With an Inadequate Response or Intolerance to Previous TNF Therapy (Cohort 2)
INTERVENTIONAL
Inicio: 9 de sept de 2016
ID: NCT02833350
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
INTERVENTIONAL
Inicio: 6 de jun de 2024
ID: NCT06056297
Terminado
Fase 2
ClinicalTrials.gov
An Open-Label Extension Study To Evaluate The Long- Term Safety And Tolerability Of Daxdilimab (Hzn-7734) In Subjects With Systemic Lupus Erythematosus
INTERVENTIONAL
Inicio: 1 de jun de 2022
ID: NCT05430854
Completado
Fase 3
ClinicalTrials.gov
A Phase IIIb, Multi-Center, Randomized, Withdrawal Study to Evaluate the Immunogenicity and Safety of Subcutaneous Administered Abatacept in Adults With Active Rheumatoid Arthritis
INTERVENTIONAL
Inicio: 1 de nov de 2007
ID: NCT00533897
Terminado
Fase 3
ClinicalTrials.gov
A Randomized, Controlled Study of Sarilumab and Methotrexate (MTX) Versus Etanercept and MTX in Patients With Rheumatoid Arthritis (RA) and an Inadequate Response to 4 Months of Treatment With Adalimumab and MTX
INTERVENTIONAL
Inicio: 1 de abr de 2013
ID: NCT01764997
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1)
INTERVENTIONAL
Inicio: 12 de ene de 2023
ID: NCT05617677
Completado
Fase 4
ClinicalTrials.gov
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
INTERVENTIONAL
Inicio: 27 de nov de 2012
ID: NCT01705977
Anterior
1
...
11
12
13
...
434
Siguiente
Filtros